Showing content from https://patents.google.com/patent/SG10202110563YA/en below:
SG10202110563YA - Ganaxolone for use in treating genetic epileptic disoders
SG10202110563YA - Ganaxolone for use in treating genetic epileptic disoders - Google PatentsGanaxolone for use in treating genetic epileptic disoders Info
-
Publication number
-
SG10202110563YA
SG10202110563YA SG10202110563YA SG10202110563YA SG10202110563YA SG 10202110563Y A SG10202110563Y A SG 10202110563YA SG 10202110563Y A SG10202110563Y A SG 10202110563YA SG 10202110563Y A SG10202110563Y A SG 10202110563YA SG 10202110563Y A SG10202110563Y A SG 10202110563YA
-
Authority
-
SG
-
Singapore
-
Prior art keywords
-
disoders
-
ganaxolone
-
treating genetic
-
epileptic
-
genetic epileptic
-
Prior art date
-
2017-11-10
Application number
SG10202110563YA
Inventor
Lorianne Masuoka
Jaakko Lappalainen
Original Assignee
Marinus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
2017-11-10
Filing date
2018-11-09
Publication date
2021-11-29
2018-11-09 Application filed by Marinus Pharmaceuticals Inc filed Critical Marinus Pharmaceuticals Inc
2021-11-29 Publication of SG10202110563YA publication Critical patent/SG10202110563YA/en
Links
- PGTVWKLGGCQMBR-FLBATMFCSA-N Ganaxolone Chemical compound C([C@@H]1CC2)[C@](C)(O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)C)[C@@]2(C)CC1 PGTVWKLGGCQMBR-FLBATMFCSA-N 0.000 title 1
- 230000001037 epileptic effect Effects 0.000 title 1
- 229950006567 ganaxolone Drugs 0.000 title 1
- 230000002068 genetic effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02Â -Â A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG10202110563YA 2017-11-10 2018-11-09 Ganaxolone for use in treating genetic epileptic disoders SG10202110563YA (en) Applications Claiming Priority (1) Application Number Priority Date Filing Date Title US201762584403P 2017-11-10 2017-11-10 Publications (1) Family ID=66438123 Family Applications (2) Application Number Title Priority Date Filing Date SG10202110563YA SG10202110563YA (en) 2017-11-10 2018-11-09 Ganaxolone for use in treating genetic epileptic disoders SG11202004329TA SG11202004329TA (en) 2017-11-10 2018-11-09 Ganaxolone for use in treating genetic epileptic disoders Family Applications After (1) Application Number Title Priority Date Filing Date SG11202004329TA SG11202004329TA (en) 2017-11-10 2018-11-09 Ganaxolone for use in treating genetic epileptic disoders Country Status (11) Families Citing this family (46) * Cited by examiner, â Cited by third party Publication number Priority date Publication date Assignee Title AU2012304412A1 (en) 2011-09-08 2014-03-27 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof US20150018327A1 (en) 2012-01-23 2015-01-15 Sage Therapeutics, Inc. Neuroactive steroid formulations and methods of treating cns disorders CN104736159A (en) 2012-08-21 2015-06-24 è¨å¥æ²»çè¡ä»½æéå
¬å¸ Methods of treating epilepsy or status epilepticus US20160031930A1 (en) 2013-03-13 2016-02-04 Sage Therapeutics, Inc. Neuroactive steroids and methods of use thereof SG10201802389SA (en) 2013-04-17 2018-04-27 Sage Therapeutics Inc 19-nor c3,3-disubstituted c21-n-pyrazolyl steroids and methods of use thereof WO2014169831A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof US20160068563A1 (en) 2013-04-17 2016-03-10 Boyd L. Harrison 19-nor neuroactive steroids and methods of use thereof RU2019126333A (en) 2013-04-17 2019-10-08 Сейдж ТеÑапÑÑÑикÑ, Ðнк. 19-NOR NEUROACTIVE STEROIDS AND WAYS OF THEIR APPLICATION LT3021852T (en) 2013-07-19 2021-04-12 Sage Therapeutics, Inc. NON - ACTIVE STEROIDS, THEIR COMPOSITIONS AND USES AU2014308621C1 (en) 2013-08-23 2022-01-06 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof EP3157528B1 (en) 2014-06-18 2023-09-13 Sage Therapeutics, Inc. Oxysterols and methods of use thereof WO2015195962A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof JOP20200195A1 (en) 2014-09-08 2017-06-16 Sage Therapeutics Inc Neuroactive steroids and formulations, and their uses ME03809B (en) 2014-10-16 2021-04-20 Sage Therapeutics Inc COMPOSITIONS AND METHODS OF TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS KR20230170816A (en) 2014-10-16 2023-12-19 ì¸ì´ì§ í
ë¼í¨í±ì¤, ì¸í¬. Compositions and methods for treating cns disorders EP3719029A1 (en) 2014-11-27 2020-10-07 Sage Therapeutics, Inc. Compositions for inducing sedation SMT202100113T1 (en) 2015-01-26 2021-05-07 Sage Therapeutics Inc Compositions and methods for treating cns disorders ES2935476T3 (en) 2015-02-20 2023-03-07 Sage Therapeutics Inc Neuroactive steroids, compositions and uses thereof IL282048B2 (en) 2015-07-06 2024-09-01 Sage Therapeutics Inc Oxysterols and methods of using them EP4316591A3 (en) 2015-07-06 2024-04-24 Sage Therapeutics, Inc. Oxysterols and methods of use thereof EP3828194B1 (en) 2015-07-06 2025-04-16 Sage Therapeutics, Inc. Oxysterols and methods of use thereof KR102408399B1 (en) 2016-03-08 2022-06-13 ì¸ì´ì§ í
ë¼í¨í±ì¤, ì¸í¬. Neuroactive steroids, compositions, and uses thereof PL3436022T3 (en) 2016-04-01 2022-08-08 Sage Therapeutics, Inc. Oxysterols and methods of use thereof WO2017193046A1 (en) 2016-05-06 2017-11-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof LT3481846T (en) 2016-07-07 2021-08-25 Sage Therapeutics, Inc. 11-substituted 24-hydroxysterols for use in the treatment of nmda related conditions MA45600A (en) 2016-07-11 2019-05-15 Sage Therapeutics Inc NEUROACTIVE STEROIDS SUBSTITUTED IN C7, C12 AND C16 AND ASSOCIATED METHODS OF USE WO2018013613A1 (en) 2016-07-11 2018-01-18 Sage Therapeutics, Inc. C17, c20, and c21 substituted neuroactive steroids and their methods of use IL315950A (en) 2016-08-23 2024-11-01 Sage Therapeutics Inc A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid ES2935057T3 (en) 2016-09-30 2023-03-01 Sage Therapeutics Inc C7 substituted oxysterols and these compounds for use as NMDA modulators TW202320799A (en) 2016-10-18 2023-06-01 ç¾åè³½åé«çå
¬å¸ Oxysterols and methods of use thereof IL293231B1 (en) 2016-10-18 2025-06-01 Sage Therapeutics Inc Oxysterols and methods of use thereof US10562930B1 (en) 2018-08-31 2020-02-18 Praxis Precision Medicines, Inc. Salts and crystal forms of GABAA positive allosteric modulator US11266662B2 (en) 2018-12-07 2022-03-08 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of postpartum depression US20200188358A1 (en) * 2018-12-14 2020-06-18 Praxis Precision Medicines, Inc. Methods for the treatment of depression CN113272315B (en) * 2018-12-26 2023-08-08 å¼ å®¶å£åå¥è´è¿çç©ç§ææéå
¬å¸ Steroid compounds and application thereof MX2021014515A (en) 2019-05-31 2022-03-22 Sage Therapeutics Inc Neuroactive steroids and compositions thereof. CN114340670A (en) 2019-07-11 2022-04-12 æ®æå
西æ¯ç²¾å¯è¯ç©è¡ä»½æéå
¬å¸ Formulations of T-type calcium channel modulators and methods of use WO2021067702A1 (en) * 2019-10-02 2021-04-08 Praxis Precision Medicines, Inc. Combinations of gaba-a receptor positive allosteric modulators and nmda antagonists, nmda negative allosteric modulators or nmda partial agonists AU2020395254A1 (en) * 2019-12-06 2022-06-02 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treating tuberous sclerosis complex IL297642A (en) * 2020-04-29 2022-12-01 Praxis Prec Medicines Inc Methods of use of t-type calcium channel modulators WO2022125408A1 (en) * 2020-12-07 2022-06-16 Marinus Pharmaceuticals, Inc Use of ganaxolone in treating an epilepsy disorder US20230321116A1 (en) * 2022-02-16 2023-10-12 Lipocine Inc. 3Alpha-OH-5Beta-Pregnan-20-One Compositions and Methods for Treating Central Nervous System Disorders WO2023060067A1 (en) * 2021-10-04 2023-04-13 Marinus Pharmaceuticals, Inc. Amorphous solid dispersion ganaxolone formulation EP4412619A1 (en) 2021-10-04 2024-08-14 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treating tuberous sclerosis complex and seizure disorders WO2024156799A1 (en) * 2023-01-27 2024-08-02 Hyloris Developments Sa Use of vitamin e tpgs as a taste masking agent for bitter drugs WO2024257008A1 (en) * 2023-06-13 2024-12-19 Biostrike Unipessoal Lda Compounds for diagnosing and treating epilepsy syndromes, methods and uses thereof Family Cites Families (10) * Cited by examiner, â Cited by third party Publication number Priority date Publication date Assignee Title US5556847A (en) * 1994-10-27 1996-09-17 Duquesne University Of The Holy Ghost Methods of effecting memory enhancement mediated by steroid sulfatase inhibitors US5888996A (en) * 1995-07-26 1999-03-30 Trustees Of Boston University Inhibition of NMDA receptor activity and modulation of glutamate-mediated synaptic activity US20150018327A1 (en) * 2012-01-23 2015-01-15 Sage Therapeutics, Inc. Neuroactive steroid formulations and methods of treating cns disorders CN104736159A (en) * 2012-08-21 2015-06-24 è¨å¥æ²»çè¡ä»½æéå
¬å¸ Methods of treating epilepsy or status epilepticus US9629853B2 (en) * 2014-05-21 2017-04-25 Wisconsin Alumni Research Foundation Uses of ganaxolone AU2016214996B2 (en) * 2015-02-06 2021-03-04 Marinus Pharmaceuticals, Inc. Intravenous ganaxolone formulations and their use in treating status epilepticus and other seizure disorders AU2016338672A1 (en) * 2015-10-16 2018-04-12 Marinus Pharmaceuticals, Inc. Injectable neurosteroid formulations containing nanoparticles KR102408399B1 (en) 2016-03-08 2022-06-13 ì¸ì´ì§ í
ë¼í¨í±ì¤, ì¸í¬. Neuroactive steroids, compositions, and uses thereof EP4233861A3 (en) * 2016-08-11 2023-10-11 Ovid Therapeutics, Inc. Compositions for treatment of essential tremor EP3612186A1 (en) * 2017-04-18 2020-02-26 Marinus Pharmaceuticals, Inc. Sustained release injectable neurosteroid formulations
Also Published As Similar Documents
RetroSearch is an open source project built by @garambo
| Open a GitHub Issue
Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo
HTML:
3.2
| Encoding:
UTF-8
| Version:
0.7.4